<SEC-DOCUMENT>0001178913-26-002062.txt : 20260410
<SEC-HEADER>0001178913-26-002062.hdr.sgml : 20260410
<ACCEPTANCE-DATETIME>20260410160707
ACCESSION NUMBER:		0001178913-26-002062
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260318
FILED AS OF DATE:		20260410
DATE AS OF CHANGE:		20260410

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Fatal Sigal
		CENTRAL INDEX KEY:			0001850994
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		26854898

	MAIL ADDRESS:	
		STREET 1:		16 KANFEY NESHARIM ST.
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5235716

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0607</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2026-03-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001534248</issuerCik>
        <issuerName>Chemomab Therapeutics Ltd.</issuerName>
        <issuerTradingSymbol>CMMB</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001850994</rptOwnerCik>
            <rptOwnerName>Fatal Sigal</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>true</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>C/O CHEMOMAB THERAPEUTICS LTD.</rptOwnerStreet1>
            <rptOwnerStreet2>10 HABARZEL ST., BUILDING C, 10TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>TEL AVIV</rptOwnerCity>
            <rptOwnerNonUSStateTerritory></rptOwnerNonUSStateTerritory>
            <rptOwnerCountry>L3</rptOwnerCountry>
            <rptOwnerZipCode>6158101</rptOwnerZipCode>
            <rptOwnerStateDescription>ISRAEL</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>American Depositary Shares</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>9728</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>American Depositary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>15222</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>American Depositary Shares</value>
                <footnoteId id="F2"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>12500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock option (right to buy American Depositary Shares)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>39.31</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-11-11</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>American Depositary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>8900</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock option (right to buy American Depositary Shares)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.44</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-11-08</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>American Depositary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>7350</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Stock option (right to buy American Depositary Shares)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>6.80</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-06-14</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>American Depositary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>25715</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The American Depositary Shares reported in this row consist of restricted share units (&quot;RSUs&quot;) that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.</footnote>
        <footnote id="F2">The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.</footnote>
        <footnote id="F3">The options reported in this row were granted to the Reporting Person by the Issuer on November 11, 2021, and are fully vested and exercisable as of the date of this report.</footnote>
        <footnote id="F4">The options reported in this row were granted to the Reporting Person by the Issuer on November 8, 2022, and vest and become exercisable according to following schedule: 25% on November 8, 2023, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on November 8, 2026.</footnote>
        <footnote id="F5">The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 14, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 15, 2027.</footnote>
    </footnotes>

    <remarks>This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.</remarks>

    <ownerSignature>
        <signatureName>/s/ Sigal Fattal</signatureName>
        <signatureDate>2026-04-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
